CLASS II Device recall · Reported 25 Jan 2017 · FDA Enforcement Report

AFX Endovascular AAA System, Endoleak Type IIIA recalled by Endologix

Endologix is recalling AFX Endovascular AAA System, Endoleak Type IIIA. The recall was initiated on 27 Dec 2016 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesThe correction is not lot specific. It applies to AFX procedures conducted after June 2013
Quantity recalled40,967

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1035-2017
FDA event ID
76075
Recalling firm
Endologix, Irvine, CA
Classification
Class II
Status
Terminated
Recall initiated
27 Dec 2016
FDA classified
18 Jan 2017
Reported
25 Jan 2017
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects

Timeline

27 Dec 2016Recall initiated by company
18 Jan 2017Classified by FDA+22 days
25 Jan 2017Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Endologix initiated a correction by updating reports for the cumulative clinical data and information on the Powerlink System and the AFX Endovascular AAA System (AFX System).

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

AFX Endovascular AAA System, Endoleak Type IIIA

Where it was distributed

Worldwide Distribution - US Distribution and to the countries of : Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey and United Kingdom.

Questions about this recall

Why was it recalled?

Endologix initiated a correction by updating reports for the cumulative clinical data and information on the Powerlink System and the AFX Endovascular AAA System (AFX System).

Which lots are affected?

The correction is not lot specific. It applies to AFX procedures conducted after June 2013

Where was it sold?

Worldwide Distribution - US Distribution and to the countries of : Austria, Belgium, Czech Republic, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Luxembourg, Monaco, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey and United Kingdom.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Endologix

All 13

Other Heart & Vascular Devices recalls

All 6,199